Critical Challenges and Landmark Practice Advances in Cancer and Thrombosis Management

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

The educational activity is designed for physicians likely to encounter patients at risk for VTE, among them: primary care physicians, hospitalist physicians, critical care specialists/intensivists, orthopedic surgeons, general surgeons, hematologists, pulmonologists, thrombosis medicine anticoagulation specialists, hospital-focused internists, surgical oncologists, and emergency medicine specialists.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent
educational grant from Eisai, Inc.
 
 

Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Continuing Education Credit:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School (UMMS and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The UMMS designates this continuing medical education activity for a maximum of 3 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosures:

Craig M. Kessler, MD
Grants/research support: sanofi-aventis, Eisai, GlaxoSmithKline, Octapharma
Consultant: sanofi-aventis, Eisai, NovoNordisk

Frederick Rickles, MD
Consultant for Pfizer, Eisai, sanofi-aventis, and Bristol-Myers Squibb
Speakers Bureau: Eisai

John Fanikos, RPh, MBA
Speakers Bureau and Consulting: Abbott Laboratories, Astra-Zeneca, Eisai Pharmaceuticals, Genentech, GlaxoSmithKline, sanofi-aventis, The Medicines Company

Program Faculty:

Craig M. Kessler, MD
Professor of Medicine and Pathology
Georgetown University Medical Center
Director of the Division of Coagulation
Department of Laboratory Medicine
Washington, DC

John Fanikos, RPh, MBA
Assistant Director of Pharmacy
Brigham and Women’s Hospital
Assistant Clinical Professor of Pharmacy
Northeastern University
Massachusetts College of Pharmacy
Boston, Massachusetts

Frederick R. Rickles, MD, FACP
Professor of Medicine, Pediatrics and Pharmacology and Physiology
The George Washington University
Washington, DC
Fellow, Center for Science and Technology
Noblis

Educational Objectives:

• Have reviewed recent trials, research, and expert analysis of issues focused on thrombosis and cancer.
• Learn about specific strategies for risk-directed prophylaxis against DVT in at risk patients with cancer.
• Learn about guidelines for DVT prophylaxis in cancer issues by the National Comprehensive Cancer Network (NCCN) and the American College of Chest Physicians (ACCP).
• Learn how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT.
• Learn how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis.
• Have the opportunity to learn the results and implications of landmark clinical trials focusing on DVT prophylaxis in patients with cancer.
• Learn how to appropriately employ the range of pharmacologic options available for thrombosis management in patients with malignancy.

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved